Improved pancreatic beta-cell function in type 2 diabetic patients after lifestyle-induced weight loss is related to glucose-dependent insulinotropic polypeptide

What Was Tested

The paper reports a study of GIP (Gastric Inhibitory Polypeptide) in the context of pancreatitis (after the acute phase), published as a clinical trial.

Restoration of insulin secretion is critical for the treatment of type 2 diabetes.

Exercise and diet can alter glucose-induced insulin responses, but whether this is due to changes in beta-cell function per se is not clear.

The mechanisms by which lifestyle intervention may modify insulin secretion in type 2 diabetes have also not been examined but may involve the incretin axis.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

Twenty-nine older, obese (aged 65 +/- 1 years; BMI 33.6 +/- 1.0 kg/m(2)) subjects, including individuals with newly diagnosed type 2 diabetes (obese-type 2 diabetic) and individuals with normal glucose tolerance (obese-NGT), underwent 3 months of nutritional counseling and exercise training. beta-Cell function (oral glucose-induced insulin secretion corrected for insulin resistance assessed by hyperinsulinemic-euglycemic clamps) and the role of glucose-dependent insulinotropic polypeptide (GIP) were examined.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Diet, Reducing, Exercise, Gastric Inhibitory Polypeptide, Glucose Clamp Technique and Hyperinsulinism.

What This Means in Plain Language

This is a clinical trial of GIP (Gastric Inhibitory Polypeptide) in people with pancreatitis (after the acute phase).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (Diabetes care), a journal based in United States.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, Pancreatitis (after the acute phase) research.